4 free views remaining today

developmental and epileptic encephalopathy 21

Description

Developmental and Epileptic Encephalopathy 21 (DEE21) is a rare autosomal recessive neurologic disorder characterized by the onset of intractable seizures in the first months of life [3]. Affected individuals have severely impaired psychomotor development with poor head control and inability to fix and follow visually [5][6]. Other features may include axial hypotonia, peripheral hypertonia, and cerebral abnormalities.

DEE21 is a severe form of developmental and epileptic encephalopathy (DEE), which refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills [10].

The onset of DEE21 is typically in the first months of life, and it is associated with early infantile epileptic encephalopathy caused by a mutation in the NECAP1 gene [7]. This condition is characterized by severe cognitive regression and intellectual disability.

In summary, DEE21 is a rare and severe neurologic disorder that affects infants and young children, causing severe developmental delay, seizures, and intellectual disability.

Additional Characteristics

  • Early infantile epileptic encephalopathy
  • Intellectual disability
  • Axial hypotonia
  • Severe impairment of psychomotor development
  • Inability to fix and follow visually
  • Peripheral hypertonia
  • Cerebral abnormalities
  • Seizures in the first months of life
  • Severe cognitive regression

Signs and Symptoms

Developmental and Epileptic Encephalopathy (DEE) Signs and Symptoms

Developmental and epileptic encephalopathy is a severe neurological disorder characterized by intellectual disability, epilepsy, and delayed or absent development. The signs and symptoms of DEE can vary in severity and presentation, but often include:

  • Intellectual Disability: Affected individuals may have significant delays or absence of developmental milestones, leading to profound mental retardation [1].
  • Seizures: Epileptic seizures are a hallmark of DEE, with various types and frequencies reported [2]. Some affected individuals may experience prolonged febrile seizures within the first year of life.
  • Developmental Delays: Poor head control, inability to fix and follow visually, and delayed or absent language skills are common features of DEE [3].
  • Hypotonia: Reduced muscle tone (hypotonia) is often observed in individuals with DEE, which can lead to difficulty walking or maintaining posture.
  • EEG Abnormalities: Electroencephalogram (EEG) findings may show various abnormalities, such as hypsarrhythmia (an irregular pattern), dyskinesia, and other seizure-related patterns [4].
  • Spastic Quadriplegia: Some affected individuals may develop spastic quadriplegia, a condition characterized by increased muscle tone and stiffness in the arms and legs.
  • Global Developmental Delay: DEE is often associated with severe global developmental delay, which can manifest as delayed or absent cognitive, motor, and language skills.

It's essential to note that the severity and presentation of DEE can vary significantly among affected individuals. A comprehensive diagnostic evaluation by a qualified healthcare professional is necessary for accurate diagnosis and management of this condition.

Additional Symptoms

  • Hypotonia
  • Seizures
  • Developmental Delays
  • Intellectual Disability
  • Global Developmental Delay
  • EEG Abnormalities
  • Spastic Quadriplegia

Diagnostic Tests

Diagnostic Tests for Developmental and Epileptic Encephalopathy 21 (DEE21)

Developmental and Epileptic Encephalopathy 21 (DEE21) is a rare genetic disorder characterized by the onset of intractable seizures in early childhood. Diagnostic tests play a crucial role in confirming the diagnosis of DEE21.

Genetic Testing

Genetic testing is a vital diagnostic tool for DEE21. It involves analyzing the patient's DNA to identify mutations in the NECAP1 gene, which is associated with this condition [2]. Next-generation sequencing (NGS) using a panel of genes related to hereditary epileptic encephalopathies can also be employed to detect the precise aetiology [4].

Clinical Investigations

In addition to genetic testing, clinical investigations are essential for diagnosing DEE21. These may include:

  • Review of medical history and physical examination
  • Neuroimaging (MRI) to rule out other conditions that may cause seizures
  • Electroencephalogram (EEG) to assess the electrical activity in the brain

Diagnostic Accuracy

The diagnostic accuracy for DEEs, including DEE21, is generally achieved through a combination of clinical investigations and genetic testing [8]. A molecular diagnosis can be made if the patient's DNA shows mutations in the NECAP1 gene.

References

  • Genetic testing is very useful in the differential diagnosis of hereditary epileptic encephalopathies. Prenatal diagnosis is possible in some cases [3].
  • The most widely used technique for genetic testing is next-generation sequencing, using a panel of up to 100 genes associated with DEEs [7].
  • Diagnostic accuracy is crucial for the effective management of DEEs and is generally achieved through a combination of clinical investigations [8].

Additional Diagnostic Tests

  • Neuroimaging (MRI)
  • Genetic Testing
  • Electroencephalogram (EEG)
  • Review of medical history and physical examination

Treatment

Treatment Options for Developmental and Epileptic Encephalopathy

Developmental and epileptic encephalopathy (DEE) is a severe form of epilepsy that affects infants and young children. While there is no cure for DEE, various treatment options are available to manage the condition and improve quality of life.

Medications Used in Treatment

Several antiseizure medications have been used to treat DEE, including:

  • Vigabatrin: Studies suggest that early institution of vigabatrin may prevent drug-resistant epilepsy and DEE [7].
  • Clobazam: This medication has been shown to be effective in reducing seizures associated with DEE [3][5].
  • Valproate: Valproate is another antiseizure medication used to treat DEE, although its effectiveness can vary depending on the individual case [5].
  • Levetiracetam: Levetiracetam has also been used to manage seizures in patients with DEE [5].

Other Treatment Options

In addition to medications, other treatment options for DEE may include:

  • Surgical interventions: In some cases, surgical procedures such as corpus callosotomy or hemispherectomy may be considered to reduce seizure activity.
  • Dietary therapies: Specialized diets such as the ketogenic diet may also be used to manage seizures in patients with DEE.

Importance of Early Intervention

Early intervention and treatment are crucial in managing DEE. Studies have shown that early institution of antiseizure medications, particularly vigabatrin, can prevent drug-resistant epilepsy and improve outcomes [7].

References:

[3] - May 23, 2022 — Antiseizure medications includes clobazam, vigabatrin, zonisamide, phenobarbital, benzodiazapines, vigabatrin, and others are used for ... [5] - by FV de Góes · 2022 · Cited by 1 — Many anti-seizure medications, such as phenobarbital 5 mg/kg/day, clobazam 1.0 mg/kg/day, valproate 50 mg/kg/day, and levetiracetam 40 mg/kg/day ... [7] - by A Pong · 2024 — There is some evidence to suggest that drug resistant epilepsy and developmental epileptic encephalopathy may be prevented with early institution of vigabatrin ...

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Differential Diagnoses for Developmental and Epileptic Encephalopathy

Developmental and epileptic encephalopathy (DEE) is a complex condition that requires accurate diagnosis to determine the underlying cause. The differential diagnoses for DEE include:

  • Early Myoclonic Encephalopathy: This is a rare epilepsy syndrome characterized by early onset of myoclonic seizures, developmental delay, and intellectual disability [1].
  • West Syndrome: Also known as infantile spasms, this condition is marked by clusters of brief muscle contractions, developmental delay, and intellectual disability [7].
  • Other Epileptic Encephalopathies: These include conditions such as Othahara syndrome, Lennox-Gastaut syndrome, and Landau-Kleffner syndrome, which are characterized by distinct electroencephalographic (EEG) patterns and varying degrees of developmental delay and intellectual disability [7].
  • GRIN2B-related Neurodevelopmental Disorder: This is a genetic disorder that affects the development of the brain and can lead to severe developmental delay, intellectual disability, and epilepsy [3].

Key Considerations for Diagnosis

When diagnosing DEE, it's essential to consider the following factors:

  • EEG Results: The EEG is a crucial tool in diagnosing DEE, as it can reveal characteristic patterns of abnormal brain activity [2].
  • Developmental History: A thorough understanding of the child's developmental history, including any signs of developmental delay or intellectual disability, is essential for accurate diagnosis [8].
  • Family History: A family history of similar conditions or genetic disorders may provide valuable clues in diagnosing DEE [9].

References

[1] Context 1 [2] Context 2 [3] Context 3 [7] Context 7 [8] Context 8

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_2812
owl#annotatedSource
t353202
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0080443
core#notation
DOID:0080443
oboInOwl#hasDbXref
MIM:615833
oboInOwl#hasExactSynonym
early infantile epileptic encephalopathy 21
rdf-schema#label
developmental and epileptic encephalopathy 21
IAO_0000115
A developmental and epileptic encephalopathy characterized by onset in the first months of life by intractable seizures and severely impaired psychomotor development that has_material_basis_in homozygous or compound heterozygous mutation in the NECAP1 gene on chromosome 12p13.
rdf-schema#subClassOf
t353847
IDO_0000664
http://purl.obolibrary.org/obo/GENO_0000148
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.